Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.0 - $4.45 $45,800 - $101,905
-22,900 Reduced 21.5%
83,600 $168,000
Q1 2024

May 14, 2024

BUY
$2.16 - $5.94 $230,040 - $632,610
106,500 New
106,500 $477,000
Q3 2023

Nov 14, 2023

SELL
$1.06 - $3.91 $63,356 - $233,700
-59,770 Reduced 85.36%
10,254 $13,000
Q2 2023

Aug 14, 2023

SELL
$3.08 - $9.55 $11,131 - $34,513
-3,614 Reduced 4.91%
70,024 $230,000
Q1 2023

May 15, 2023

BUY
$4.0 - $7.02 $2,960 - $5,194
740 Added 1.02%
73,638 $302,000
Q4 2022

Feb 14, 2023

SELL
$5.65 - $7.86 $366,526 - $509,893
-64,872 Reduced 47.09%
72,898 $427,000
Q3 2022

Nov 14, 2022

SELL
$4.63 - $8.0 $476,700 - $823,672
-102,959 Reduced 42.77%
137,770 $931,000
Q2 2022

Aug 15, 2022

BUY
$2.84 - $5.0 $129,018 - $227,145
45,429 Added 23.26%
240,729 $1.11 Million
Q1 2022

May 13, 2022

BUY
$3.74 - $6.63 $462,638 - $820,131
123,700 Added 172.77%
195,300 $779,000
Q3 2021

Nov 12, 2021

SELL
$8.56 - $14.47 $69,336 - $117,207
-8,100 Reduced 10.16%
71,600 $675,000
Q2 2021

Aug 12, 2021

SELL
$13.28 - $18.07 $150,064 - $204,191
-11,300 Reduced 12.42%
79,700 $1.08 Million
Q1 2021

May 17, 2021

BUY
$15.31 - $26.52 $62,771 - $108,732
4,100 Added 4.72%
91,000 $1.47 Million
Q4 2020

Feb 03, 2021

SELL
$16.84 - $27.59 $72,412 - $118,637
-4,300 Reduced 4.71%
86,900 $2.31 Million
Q3 2020

Nov 16, 2020

BUY
$16.2 - $25.7 $221,940 - $352,090
13,700 Added 17.68%
91,200 $1.7 Million
Q2 2020

Aug 12, 2020

BUY
$5.24 - $23.4 $100,608 - $449,280
19,200 Added 32.93%
77,500 $1.81 Million
Q1 2020

May 06, 2020

BUY
$4.41 - $9.28 $257,103 - $541,024
58,300 New
58,300 $340,000
Q2 2019

Aug 14, 2019

SELL
$3.84 - $6.4 $65,280 - $108,800
-17,000 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$3.51 - $7.3 $14,040 - $29,200
4,000 Added 30.77%
17,000 $89,000
Q4 2018

Feb 11, 2019

BUY
$3.45 - $9.72 $44,850 - $126,360
13,000 New
13,000 $53,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $216M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.